Breaking News

French Planes Carry Out First Strikes on Iraq Islamic State Targets
Tweet TWEET

Fresenius Obtains $6 Billion of Bridge Loans for Rhoen Purchase

Fresenius SE said it obtained $6.1 billion of short-term loans to fund its bid for Rhoen Klinikum AG (RHK), cementing its position as Germany’s biggest operator of private hospitals.

The so-called bridge financing, which includes a 3.1 billion-euro ($3.96 billion) tranche and a $2.15 billion portion, will be refinanced with long-term debt that includes high-yield bonds and loans, Bad Homburg, Germany-based Fresenius said in an offer document on its website.

The long-term debt will include 700 million euros and $200 million in facility A, 500 million euros and $1.2 billion in facility B, and a 400 million-euro revolving credit, all of which will have maturities between five and seven years, according to the filing. There will also be 1.5 billion euros and $750 million of a high-yield bridge facility that can be extended to seven years if it is not refinanced with senior bonds within the first year, Fresenius said.

Fresenius set a June 27 deadline for Rhoen Klinikum investors to tender their shares in its 3.1 billion-euro bid to buy the German hospital operator. The nation’s financial regulator approved the offer on May 18.

Deutsche Bank AG, JPMorgan Chase & Co., Societe Generale SA, Credit Suisse Group AG and UniCredit SpA (UCG) underwrote the debt financing.

Fresenius completed a 1 billion-euro capital increase on May 11 to help finance the deal, which will build annual revenue at the company’s hospital unit to 6 billion euros, about 8 percent of the German market.

To contact the reporter on this story: Patricia Kuo in London at pkuo2@bloomberg.net

To contact the editor responsible for this story: Faris Khan at fkhan33@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.